New Delhi: The trade deal between India and the US is a game-changer for the Indian MedTech and pharma sectors, said industry experts. In a historic move, the US has announced a reduction in tariffs on Indian exports to 18 percent from 50 percent, which is a constructive development for the trade relations.
The US is India’s largest export destination, accounting for about 20 per cent of total exports. The Association of Indian Medical Devices (AiMeD), hailed the deal and noted that it can prove to be a “vital boost for our manufacturers, enhancing global competitiveness, spurring investments, and creating jobs”.
The US tariff cut to 18 per cent on Indian goods also provides Indian medical devices a competitive edge over Chinese counterparts, which face higher Section 301 tariffs typically at 25 per cent plus additional hikes (up to 50-60 per cent on some items like respirators).
Previously, India endured up to 50 per cent duties while China had around 30 per cent, but the new deal aligns India’s rate below China’s base, favouring India amid China+1 diversification.
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) also highlighted the positive implications of the India-US trade deal for the Indian pharma sector. The deal also fosters greater market access for Indian generics and biosimilars, strengthening India’s position as the global leader in affordable medicines.
By enhancing trade ties, streamlining regulatory processes, and ensuring supply chain resilience, this agreement will drive growth in India's pharmaceutical exports, unlock new opportunities for innovation, and reinforce the country’s critical role in global healthcare.
